Cancer-focused genetic and molecular testing laboratory serving oncologists, hospitals and pharmaceutical companies.
Cancer-focused genetic and molecular testing laboratory serving oncologists, hospitals and pharmaceutical companies.
Clinical testing carries it: labs analyse tumour samples sent by pathologists and oncologists, and it bills the patient's insurer or Medicare for each test, so payer coverage and rates matter. A smaller pharma-services arm runs lab work for drug trials under contract. It bought Inivata in 2021 to add blood-based tests for detecting residual disease.
Moat: narrow (scale, data). One of the largest independent cancer-testing labs, with broad test menu and pharma trial-services relationships.
Headquarters: Fort Myers, Florida · Founded: 2001 · Employees: 2,500
Size NeoGenomics (NEO) is a United States Health Care company (Medical/Nursing Services) with a market value of $1.98B, the 1778th largest of 3,085 United States companies the cockpit tracks. Shares closed at $15.29 on 18 Nov 2026.
Performance Over six months the shares gained 71.8%, against +19.1% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue grew 11.1% over the last twelve months (peer median +6.3%); the operating margin is -5.9% (peer median 7.5%).
Valuation It trades at 53.5× forward earnings against a peer median of 33.8× (5th most expensive of 17).
Capital Return on invested capital runs 16.1 points below its cost of capital (12.8% WACC).
Next results Next results expected around 23 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $788M | $727M | $661M | $592M | $510M |
| Revenue growth | — | +10% | +12% | +16% | — |
| Gross profit | $336M | $283M | $257M | $209M | $173M |
| EBITDA | $18.8M | $1.75M | $852,000 | -$24.1M | -$71.4M |
| Net income | -$32.3M | -$108M | -$78.7M | -$88.0M | -$144M |
| Free cash flow | -$28.6M | -$21.8M | -$34.0M | -$30.7M | -$96.9M |
| Capital expenditure | $32.9M | $27.0M | $41.1M | $28.8M | $30.9M |
| Total debt | $449M | $409M | $605M | $612M | $611M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| NeoGenomics NEO | $1.98B | +72% | +11% | -6% | 53.5× | n/a |
| Labcorp LH | $30.1B | +44% | +6% | 11% | 19.3× | 14.5% |
| Quest Diagnostics DGX | $28.6B | +34% | +9% | 15% | 22.4× | 7.2% |
| Guardant Health GH | $19.6B | +26% | +42% | -39% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NEO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.0% | -0.3% | 6th lowest of 21 |
| 6-month return | +71.8% | +19.1% | 3rd highest of 21 |
| Distance from 52-week high | -24.1% | -19.6% | 10th lowest of 21 |
| Revenue growth (TTM) | +11.1% | +6.3% | 9th highest of 21 |
| Operating margin | -5.9% | 7.5% | 4th lowest of 21 |
| Forward P/E | 53.5× | 33.8× | 5th most expensive of 17 |
| ROIC minus cost of capital | -16.1 pp | -3.4 pp | 4th lowest of 20 |
| Net debt / EBITDA | 16.5× | 1.1× | 2nd most indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| NeoGenomics NEO | United States | $1.98B | +72% | +11% | -6% | 53.5× | n/a | n/a |
| Azenta AZTA | United States | $2.03B | +162% | +5% | -2% | 83.2× | 38.0% | +3.9% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.86B | +20% | +26% | 15% | 77.1× | 43.0% | +26.9% |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.86B | +5% | -3% | 7% | 29.9× | 5.4% | -6.1% |
| AddLife ALIF-B.ST | Sweden | $2.13B | +15% | +2% | 8% | 39.0× | 21.1% | +14.6% |
| Emeis EMEIS.PA | France | $1.78B | -33% | +4% | 3% | n/a | 21.2% | +8.5% |
| Addus HomeCare ADUS | United States | $2.25B | +29% | +12% | 11% | 16.2× | 4.0% | +13.2% |
| Dian Diagnostics 300244.SZ | China | $1.70B | +1% | -5% | 9% | 21.8× | 0.3% | -1.1% |
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.69B | +18% | +24% | 32% | 63.0× | 40.4% | +16.7% |
| Aveanna Healthcare AVAH | United States | $2.37B | +41% | +17% | 12% | 12.2× | 7.7% | +10.2% |
| Pediatrix Medical MD | United States | $2.41B | +37% | +2% | 12% | 12.4× | -4.4% | +2.0% |
| Personalis PSNL | United States | $1.62B | +88% | +17% | -157% | n/a | n/a | n/a |
| Sonida Senior Living SNDA | United States | $1.59B | -11% | +70% | -8% | n/a | n/a | n/a |
| Ambea AMBEA.ST | Sweden | $1.59B | +28% | +11% | 9% | 15.2× | 1.1% | +7.7% |
| GeneDx WGS | United States | $1.56B | +16% | +15% | -14% | 54.2× | n/a | n/a |
| agilon health AGL | United States | $1.52B | +12% | +2% | -2% | 34.1× | n/a | n/a |
| Meinian Onehealth Healthcare 002044.SZ | China | $2.60B | -27% | -4% | 9% | 49.6× | 4.2% | +5.7% |
| Teladoc Health TDOC | United States | $1.47B | +24% | -2% | -5% | n/a | -6.4% | +18.3% |
| H.U.Group 4544.T | Japan | $1.44B | +24% | +1% | 3% | 39.9× | 9.7% | +2.1% |
| U.S. Physical Therapy USPH | United States | $1.42B | +53% | +10% | 10% | 29.4× | 18.8% | +13.0% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.36B | -47% | +8% | 3% | 33.5× | 3.5% | -5.1% |